← Leaderboards
Andrew Peter Selwyn
Brigham And Women'S Hospital
$36,640
Attributed
$36,640
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $19.8K · FY2006–08$20K$15K$10K$5K$0
'06
'07
'08
Funding mix
By agency
NIH$36,640 · 4
By mechanism
M01$36,640 · 4
Top collaborators
No co-investigators on record.
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- James Kuang-Jan Liao$22,168,806
- Samia Mora$13,080,456
- Robert J Glynn$12,512,252
- Joann Elisabeth Manson$50,755,529
- Joseph Loscalzo$36,255,197
Others in their field
Top investigators on “Vasomotion”
- Gervasio A Lamas · Mount Sinai Medical Center (Miami Beach)$18,150,573
- David Kleinfeld · University Of California, San Diego$13,024,942
- David G Harrison · Vanderbilt University Medical Center$8,016,376
- Bruce R Rosen · Massachusetts Institute Of Technology$4,941,060
- Jeffrey R. Bender · Yale University$4,888,176
- Li-Huei Tsai · Massachusetts Institute Of Technology$4,690,463
Research focus
VasomotionAntihypercholesterolemic AgentCardiovascular Disorder ChemotherapyClinical ResearchClinical TrialsCoronary ArteryCoronary DisorderHuman SubjectHuman Therapy EvaluationVascular EndotheliumVasodilationAcetylcholineRosuvastatinSourceCrestorFundingGrantHeart DiseasesUnited States Food And Drug AdministrationUnited States National Institutes Of HealthInflammationInstitutionInterestLeukocytes
Grant awards (6)
RHO-KINASE IN PATIENTS WITH ATHEROSCLEROSIS: EFFECTS OF STATINS$2,189
M01 · FY2008 · RR · contact PI
RHO-KINASE IN PATIENTS WITH ATHEROSCLEROSIS: EFFECTS OF STATINS$14,669
M01 · FY2007 · RR · contact PI
RHO-KINASE IN PATIENTS WITH ARTHEROSCLEROSIS: EFFECTS OF STATINS$19,782
M01 · FY2006 · RR · contact PI
TREATMENT OF ENDOTHELIAL DYSFUNCTION$0
M01 · FY2002 · RR
TREATMENT OF ENDOTHELIAL DYSFUNCTION$0
M01 · FY2001 · RR
TREATMENT OF ENDOTHELIAL DYSFUNCTION$0
M01 · FY2000 · RR